Related Experiment Videos
Cyclosporin maintenance therapy for severe atopic dermatitis
M J Korstanje1, W J van de Staak
1Department of Dermatology, Academic Hospital Maastricht, The Netherlands.
Acta Dermato-Venereologica
|January 1, 1991
Summary
Cyclosporin A (CsA) effectively treated chronic severe atopic dermatitis in most patients. The minimal effective dose varied, averaging 4.0 mg/kg/day, but side effects may limit long-term use.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis is a chronic inflammatory skin condition.
- Effective long-term treatments for severe atopic dermatitis are needed.
- Cyclosporin A is an immunosuppressant with potential therapeutic applications.
Purpose of the Study:
- To evaluate the efficacy and determine the minimal effective dose of Cyclosporin A (CsA) for chronic severe atopic dermatitis.
- To assess the feasibility of maintenance therapy with CsA in this patient population.
Main Methods:
- A cohort of twelve patients with chronic severe atopic dermatitis received CsA at 5.0 mg/kg/day.
- Dose reduction was implemented after week six to identify the minimal effective dose (MED).
- MED was defined as the lowest dose maintaining therapeutic response.
Main Results:
- Eleven out of twelve patients demonstrated a good therapeutic response to CsA.
- The MED fluctuated based on disease severity, with a mean of approximately 4.0 mg/kg/day.
- Potential limitations include side effects, similar to those seen in psoriasis treatment.
Conclusions:
- Cyclosporin A shows promise as an effective maintenance therapy for chronic severe atopic dermatitis.
- The minimal effective dose of CsA is variable and requires careful titration.
- Further investigation into managing CsA-related side effects is warranted for long-term treatment.